Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ionis Touts Inotersen's Convenience As Phase III Safety Data Disappoints

Executive Summary

Although inotersen met efficacy endpoints in Phase III familial amyloidosis study, adverse event rates raised a red flag and give Alnylam's competing patisiran an edge on safety, at least for now.

You may also be interested in...



Pfizer May Enjoy Blockbuster Cardiomyopathy Success With Tafamidis

Although tafamidis has been stalled at FDA for transthyretin-mediated polyneuropathy, Pfizer may have found a different path toward US approval with cardiovascular outcomes data in cardiomyopathy.

Keeping Track: A Little Bit Of (Nearly) Everything

The latest drug development news and highlights from our US FDA Performance Tracker.

Keeping Track: A Massive Week Of Agency Approvals

The latest drug approval and development news from our US FDA Performance Tracker.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID052006

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel